Get the Daily Brief
Latest Biotech News
CMS rolls out voluntary model: Medicare to expand GLP-1 coverage
CMS launched a voluntary payment model designed to expand Medicare coverage of GLP-1 weight-loss drugs, the agency announced. The model lets participating Medicare plans cover GLP-1s under new...
FDA greenlights Yartemlea — first therapy for deadly stem-cell transplant complication
The FDA approved Omeros’s complement-targeting drug Yartemlea for a severe, potentially fatal complication of hematopoietic stem cell transplants, the company announced in regulatory coverage....
J&J cuts bait — ditches $1.25 billion eczema asset
Johnson & Johnson halted development of an experimental eczema drug it acquired for $1.25 billion, the company disclosed, after the candidate failed to meet internal efficacy standards. The...
Biohaven’s potassium channel drug fails Phase 2 — second mid‑stage setback
Biohaven reported that its potassium channel modulator failed a Phase 2 trial in major depressive disorder, marking a second mid‑stage clinical setback for the company’s experimental program. The...
New antibodies... neutralize Marburg and Ravn — broad filovirus candidate emerges
Researchers reported discovery of potent cross‑neutralizing antibodies that target both Marburg virus and the related Ravn virus, with findings published in npj Viruses. The antibodies bind...
Smart AAVs respond to tumors: design framework boosts targeting
Researchers published an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to tumor microenvironment cues to improve targeting and intratumoral...
New study maps CAR‑T neurotoxicity — safety pathways identified
Recent research advanced understanding of neurotoxicity associated with CAR‑T cell therapies, mapping hemodynamic and cellular events that precede neuroimmune adverse events. The work synthesizes...
SpatialBench: benchmark exposes agents’ demo‑to‑deployment gap
Authors introduced SpatialBench, a suite of 146 verifiable spatial‑biology analysis problems across five platforms and seven task categories, designed to benchmark AI agents on real laboratory...
Nanovaccines for HCC: engineered particles prime liver tumor immunity
Researchers highlighted nanovaccine platforms engineered to stimulate immune responses against hepatocellular carcinoma (HCC), reporting preclinical data that show enhanced antigen presentation...
Targeted protein degradation... raises cross‑species health and ecological questions
A recent review examined targeted protein degradation technologies and their biological impacts across health and species, outlining therapeutic promise alongside ecological and safety...
FDA approves Yartemlea: first approved therapy for a fatal stem‑cell transplant complication
The FDA granted approval to Omeros’s complement‑system drug Yartemlea to treat a severe, potentially fatal complication following hematopoietic stem cell transplantation. The action, reported by...
CMS unveils voluntary payment model – expands Medicare coverage for GLP‑1 weight‑loss drugs
The Centers for Medicare & Medicaid Services launched a voluntary payment model aimed at expanding Medicare coverage for GLP‑1 class weight‑loss drugs, a move reported as part of the Trump...
J&J drops eczema candidate – $1.25bn acquisition yield slashed
Johnson & Johnson discontinued its experimental eczema drug JNJ‑5939 (NM26) after the candidate failed to meet efficacy standards in a mid‑stage trial, the company disclosed. J&J acquired the...
Biohaven’s ion‑channel drug fails Phase‑2 – depression program stumbles
Biohaven announced that its potassium‑channel modulator failed a Phase‑2 trial in major depressive disorder, marking a second mid‑stage setback for the program. The company said the candidate did...
Study maps CAR‑T neurotoxicity mechanisms – route to safer cell therapies
A new study released this year advanced understanding of neurotoxicity associated with CAR‑T cell therapies, detailing clinical and molecular features that underlie treatment‑related neurological...
Engineered AAVs: vectors that sense the tumor microenvironment and adapt
Researchers unveiled an intelligent design framework for adeno‑associated virus (AAV) vectors that dynamically respond to tumor microenvironment cues to improve tumor targeting and reduce...
Nanovaccines for HCC: engineered particles enter immunotherapy pipeline
A study described nanovaccine platforms designed to stimulate immune responses against hepatocellular carcinoma (HCC), reporting preclinical efficacy in models and outlining translational routes...
SpatialBench exposes demo‑to‑deployment gap for AI agents in biology
SpatialBench, a new benchmark suite introduced by software and computational biology researchers, revealed major weaknesses in current agent‑based tools when applied to real spatial biology...
SyBValS launches to validate biological pathway maps and curb errors
A new service, SyBValS (System Biology Validation Service), was introduced to validate computationally inferred biological pathways and flag annotation errors that commonly mislead downstream...
Targeted protein degradation – review flags health and ecological considerations
A comprehensive review evaluated the therapeutic promise of targeted protein degradation (TPD) technologies and described potential health‑ and species‑level impacts of deploying degrading agents...